United Therapeutics Corporation

• UTHR Stock Price 24h change: +0.47%. From 468.07 USD to 470.26 USD. The slight uptick followed a period of consolidation, supported by positive analyst sentiment and new board appointments.
• From a technical perspective, UTHR is in a "long-term bullish consolidation" phase. It is trading above its 200-day moving average (~376 USD) but remains below its recent all-time high of 519.99 USD. The Relative Strength Index (RSI) is neutral, and the 50-day moving average (~484 USD) serves as immediate resistance, suggesting the stock is digesting previous gains.
• United Therapeutics appointed Dr. Kevin J. Tracey, a renowned expert in inflammatory and infectious diseases, to its Board of Directors on January 22, 2026.• CEO Martine Rothblatt presented at the J.P. Morgan Healthcare Conference, highlighting the upcoming unblinding of pivotal clinical data for idiopathic pulmonary fibrosis (IPF) treatments within the next three months.• Ledyard National Bank and other institutional investors like BAM Wealth Management initiated new positions in UTHR, signaling continued professional confidence in its pulmonary hypertension franchise.
• The FDA issued a draft policy on the use of Minimal Residual Disease (MRD) as a surrogate endpoint to accelerate approvals for certain oncology biotherapeutics, potentially shortening drug development timelines.• Industry leaders in the pharmaceutical and MedTech sectors called for a structured funding framework for innovation and R&D ahead of the 2026 budget cycles, focusing on complex therapies and patient access.

• UTHR Stock Price 24h change: -1.50%. From 471.99 USD to 464.93 USD. The stock experienced a decline as part of a short-term bearish phase following its December peaks, with investors reassessing valuations despite a record-breaking 2025.
• From a technical perspective, UTHR presents a "short-term bearish correction within a long-term bull market": while the 200-day moving average (~485) remains a key structural level, short-term indicators like the 14-day RSI (36.3) and MACD (-4.68) signal selling pressure. The stock is currently testing immediate support near 460-462.
• United Therapeutics presented a strategic update at the 44th Annual J.P. Morgan Healthcare Conference on Jan 12, highlighting progress in its organ transplantation pipeline and core PAH franchise.
• UBS Group recently raised its price target for UTHR to $645 (Jan 6), maintaining a "buy" rating based on strong earnings growth forecasts of ~9.3% for fiscal 2025.
• Beam Therapeutics surged 22% on Jan 12 after the FDA agreed to a biomarker-based accelerated approval path for its lead gene-editing program, BEAM-302.
• IO Biotech shares plunged over 50% on Jan 21 after the company announced it is exploring strategic alternatives following a Phase 3 trial failure for its lead cancer vaccine.